Gastric adenocarcinoma carries high mortality despite modern multimodal therapy. Reliable biomarkers that refine prognosis and suggest therapeutic strategies are needed. We evaluated the clinicopathologic and prognostic significance of folate receptor-alpha (FOLR1) expression in a large single-institution cohort. We retrospectively analyzed 259 gastrectomy specimens (2016–2025). Immunohistochemistry included FOLR1 (H-score 0–300), HER2, PD-L1 (CPS; positive if ≥ 1), p53 status, and MMR proteins (MLH1/MSH2/MSH6/PMS2). The FOLR1 cut-off for recurrence-free survival (RFS) was derived by Receiver operating characteristic(ROC) analysis. Associations were tested with Chi-square or Fisher’s exact tests and Spearman correlation; survival was assessed by Kaplan–Meier and Cox regression. ROC for RFS yielded an area under the curve (AUC) of 0.653 (95% CI 0.578–0.728; p < 0.001) and defined a FOLR1 H-score cut-off of 40; ROC for overall survival (OS) was not significant (AUC 0.528; p = 0.443). Using this threshold, FOLR1-high tumors (≥ 40; n = 48) showed significantly shorter RFS (mean 24.1 vs 266.6 months; log-rank p < 0.001) and shorter OS (mean 32.4 vs 53.9 months; p = 0.047) than FOLR1-low tumors. On univariate analysis, FOLR1-high predicted inferior RFS (HR 4.15; 95% CI 2.67–6.47; p < 0.001); in multivariate Cox modeling it remained an independent predictor (HR 1.99; 95% CI 1.15–3.45; p = 0.015). FOLR1-high status associated with advanced T stage ( p = 0.045), vascular invasion ( p < 0.001), higher M1 frequency ( p < 0.001), and proximal location ( p = 0.038). It correlated with PD-L1 positivity ( p < 0.001; FOLR1 H-score vs PD-L1 CPS Spearman r = 0.286; p < 0.001), HER2 positivity ( p < 0.001), and p53 mutant pattern ( p < 0.001), and was inversely associated with MMR deficiency ( p = 0.010). N-stage distribution was not different overall, although a linear trend toward higher nodal stage with FOLR1-high was observed ( p = 0.013). No significant associations were found with Lauren or WHO subtype, histologic grade, lymphatic or perineural invasion, extracapsular extension, neoadjuvant therapy, age, or sex. High FOLR1 expression identifies a biologically aggressive subset of gastric adenocarcinoma with inferior RFS and independent prognostic value. Its concurrent association with PD-L1 and HER2, together with relative absence in dMMR tumors, supports biomarker-guided strategies that consider FOLR1 alongside HER2 and PD-L1, and provides a rationale to explore FOLR1-targeted therapies in selected patients.